Zymeworks Receives US FDA Approval for Ziihera and $25M 'Milestone Payment' From Jazz Pharmaceuticals (Eligible for $1 Billion+) FDA Grants U.S. Approval of Ziihera (zanidatamab-hrii) for the ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $15.67, a high estimate of $28.00, and a low estimate of $10.00. Surpassing the previous average price target ...
Ziihera is one of several variations of the bispecific antibody Zanidatamab that Zymeworks developed for treating various types of cancer, and one of three in the advanced “pivotal” trial phase.
The bispecific antibody zanidatamab is now the first HER2-targeted therapy approved for patients with locally advanced or metastatic HER2-positive biliary tract cancer.